Lv0
0 积分 2022-02-20 加入
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management
1天前
待确认
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
11个月前
已完结
Characterization of Heterotopic and Orthotopic Syngeneic MOC1 and MOC2 Tumor Models
11个月前
已完结
皖公网安备34019202002308
